FUNDAMENTALS |
MarketCap: |
18.59 mill
|
EPS: |
-0.870
|
P/E: |
-0.100
|
Earnings Date: |
Apr 01, 2024 |
SharesOutstanding: |
206.76 mill
|
Avg Daily Volume: |
37.83 mill
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Sell
|
|
Return On Asset: |
Sell
|
|
DE: |
Strong Buy
|
|
P/E: |
Neutral
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.100 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-0.02x
|
Company: PE -0.100 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0699 - 0.110
( +/- 22.25%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2023-08-14 | Jayasuriya Anula | Buy | 68 568 | Common Stock |
2023-07-01 | Jayasuriya Anula | Buy | 1 718 | Common Stock |
2023-07-01 | Jayasuriya Anula | Sell | 1 718 | Restricted stock units |
2023-08-14 | Siegel Jonathan B. | Buy | 68 568 | Common Stock |
2023-08-14 | Micek John | Buy | 68 568 | Common Stock |
INSIDER POWER |
80.36
|
Last
99 transactions |
Buy:
5 141 574 | Sell:
492 412 |
Forecast:
16:00 - $0.0866
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.0866
Forecast 2: 16:00 - $0.0866
Forecast 3: 16:00 - $0.0866
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.0899 (23.32% )
|
Volume |
58.42 mill
|
Avg. Vol. |
37.83 mill
|
% of Avg. Vol |
154.43 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For JAGX
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.